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Abstract
Background: Adherence to good methodological quality is necessary to minimise bias in randomised conrolled trials (RCTs).
Specific trial characteristics are associated with better trial quality, but no studies to date are specific to HIV/AIDS or African
trials. We postulated that location may negatively impact on trial quality in regions where resources are scarce.
Methods: 1) To compare the methodological quality of all HIV/AIDS RCTs conducted in Africa with a random sample of
similar trials conducted in North America; 2) To assess whether location is predictive of trial quality. We searched MEDLINE,
EMBASE, CENTRAL and LILACS. Eligible trials were 1) randomized, 2) evaluations of preventive or treatment interventions for
HIV/AIDS, 3) reported before 2004, and 4) conducted wholly or partly (if multi-centred) in Africa or North America. We
assessed adequacy of random generation, allocation concealment and masking of assessors. Using univariate and
multivariate logistic regression analyses we evaluated the association between location (Africa versus North America) and
these domains.
Findings: The African search yielded 12,815 records, from which 80 trials were identified. The North American search yielded
13,158 records from which 785 trials were identified and a random sample of 114 selected for analysis. African trials were
three times more likely than North American trials to report adequate allocation concealment (OR=3.24; 95%CI: 1.59 to
6.59; p,0.01) and twice as likely to report adequate generation of the sequence (OR=2.36; 95%CI: 1.20 to 4.67; p=0.01),
after adjusting for other confounding factors. Additional significant factors positively associated with quality were an a priori
sample size power calculation, restricted randomization and inclusion of a flow diagram detailing attrition. We did not
detect an association between location and outcome assessor masking.
Conclusions: The higher quality of reporting of methodology in African trials is noteworthy. Most African trials are externally
funded, and it is possible that stricter agency requirements when leading trials in other countries and greater experience
and training of principal investigators of an international stature, may account for this difference.
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Introduction
Good methodological quality is necessary to minimise bias in
randomised controlled trials (RCTs) [1]. Previous studies have
shown that certain trial characteristics are related to methodolog-
ical quality. These include the disease category under study [2,3],
whether the trial was multi- or single-centred [2,4], whether
approval by an ethics committee was obtained [5], the type of
intervention [6], the type of journal where the trial was reported
[6,7], inclusion of a clear definition of the primary outcome [4],
and the source of funding [2,8]
Commentators have drawn attention to the challenges of
conducting high quality trials in resource-poor settings [9–11].
Within the HIV/AIDS field, non-African researchers conduct-
ing trials within Africa on behalf of external agencies have
reportedly prioritised speed and efficiency over ethical approval
and due process, raising questions regarding the quality of such
trials [12–14]. However, evidence linking location with trial
quality appears limited to case reports of individual studies.
Therefore, our principal aim was to comprehensively evaluate
whether the reported methodological quality of trials in Africa
differs from that of trials conducted in a better-resourced
region of the world, North America. Furthermore, given the
concerns about location and trial quality in the HIV/AIDS
field, we focused on HIV/AIDS trials conducted in both
continents.
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Identification of African trials
We have described our searches for the African trials extensively
elsewhere [15]. Briefly, in the absence of any Africa-specific trials
database, we searched the following databases to ensure adequate
identification of all possibly relevant trials conducted in Africa and
published before 2004: MEDLINE, EMBASE, the Cochrane
Central Register of Controlled Trials (CENTRAL) and LILACS;
with the assistance of an experienced information specialist.
E M B A S Ea n dL I L A C Sw e r ei n c l u d e dt om a x i m i s et h ey i e l do f
trials from Francophone and Lusophone Africa preferentially
reported in French or Portuguese-language journals. Our search
strategy involved a combination of three main stages: to identify
records pertaining to any aspect of the prevention or treatment of
HIV or AIDS, conducted in any country in Africa, and which were
likely to be randomised controlled trials (see Table 1). We searched
the electronic databases in the second halfof 2004, ensuring adequate
capture of all publications up to 2003 by taking account of the lag
between publication of the trial report and indexing in the database.
If we identified a trial with only baseline results reported before 2004
we then searched for any future trial reports regardless if these were
published after 2003. An epidemiologist fluent in Portuguese assessed
the Portuguese abstracts identified from the LILACS database.
Identification of North American trials
We replicated the above search methods to identify North
American HIV/AIDS trials, substituting the location phase with
terms and text specific to the North American continent. This was
defined geographically as Canada, the United States (US) and
Greenland excluding the Caribbean and Central America [16]. As
the comparison was intended to be between poorly and richly
resourced regions, Mexico was not included in our definition. We
searched MEDLINE, EMBASE and CENTRAL in mid 2005.
Trial eligibility and data extraction
For the African trials, one author checked each abstract against
our eligibility criteria for randomised trials (Table 1). Two
experienced hand-searchers also read all the retrieved abstracts to
identify those that reported controlled trials, regardless of location
or disease profile. This dataset was then checked by another author
for eligible African randomized trials and compared with the first
dataset for level of agreement. We obtained the full article for all
records judged to be potentially eligible from both datasets or about
whichwewereuncertain.Wherenecessary,translationfromFrench
was conducted by a researcher fluent in the language. One author
read all potentially eligible articles, determined final eligibility and
extracted data for each trial into a customised MS Access database.
To capture trial quality, we used the domain approach recom-
mended by Juni et al. [17]and appraised the adequacy of the
generation of the random sequence and allocation concealment, the
masking of assessors, and the degree of loss-to-follow-up or attrition
in each trial (see Table 2 for definitions). We developed a
hierarchical decision-making process for missing or unclear data.
Multiple reports for a single trial were linked and data from all
relevant reports was assessed.
For the North American trials, the abstracts were read by the two
trained hand-searchers and those they identified as randomised
trials were further checked by NS for eligibility using the identical
inclusion criteria for African trials substituting North America for
Africa (Table 1). A consecutive sample of 500 of the records
identified by the hand-searchers was checked by another investiga-
tor (JV) and we resolved differences by discussion. NS extracted key
characteristics for each of the potentially eligible trial abstracts. We
sought to create a random sample of the North American trials, at
least as large as the African dataset, for our comparison. We
randomly sorted these records using the [sort random]function in
STATA 8 and then selected the first 150 of these for analysis. To
confirm that the sample was broadly representative of the full
dataset we compared key trial characteristics between those records
included in the sample with those excluded from the sample. NS
then conducted data extraction for the North American trials
included in the random sample, as had been done for the African
trials. As part of a capacity development initiative, two African
research assistants conducted duplicate data extraction for 20% of
these trials serving as an additional check.
Table 1. Inclusion and exclusion criteria for randomized controlled trials in Africa.
Inclusion criteria Exclusion criteria
Intervention Efficacy or effectiveness of HIV/AIDS-specific intervention on clinical
outcomes and/or viral load, including:
Safety, acceptability and dose-finding trials with no
measurement of efficacy or effectiveness, including:
N pilot studies of efficacy; N comparisons of doses of drugs as a prelude to investigating
establishing efficacy (so-called ‘dose-finding’ trials)
N comparisons of the pharmacokinetic activity of drugs if the effects
on clinical outcomes and/or viral load are also known to have
been measured;
N comparison of doses of drugs with established efficacy if the
effects on clinical outcomes and/or viral load are also known to
have been measured
Efficacy or effectiveness of non-HIV/AIDS specific intervention, but
with a sub-group of at least 5% HIV-positive participants and a
minimum of 10 such people, on clinical outcomes and/or viral load
Trials assessing preventive behavioural interventions in people
who were not HIV- positive without measuring HIV incidence as
an outcome
Location All or some of the randomized participants were resident in Africa
(includes multinational trials with recruitment in Africa)
Trials that randomized Africans living outside the continent,
and no-one resident in Africa
Participants Infected with HIV-1, HIV-2 or dually infected, or in the case of prevention
trials, HIV-negative, but at risk of HIV
Trial Date Reported prior to 2004 (if preliminary data only, authors contacted
for additional results)
doi:10.1371/journal.pone.0003491.t001
Location Matters
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3491Statistical analysis
Statistical analysis was conducted in STATA 8. Dichotomous
trial characteristics of African trials were compared with North
American trials using univariate logistic regression. Results are
presented as Odds Ratio (OR), the 95% Confidence Interval (CI)
and the p-value for each cross-tabulation. Variables with more
than two categories were collapsed into binary variables (see
Table 3). All continuous variables were assessed for normality and
compared using the Wilcoxon rank sum test (if the distribution was
non-normal) or the Student’s unpaired t test (if normally
distributed). We transformed independent continuous variables
with skewed distributions to normality for analysis.
Univariate logistic regression was conducted for each of the
dependent quality variables against all independent variables [18].
The independent variables were those trial characteristics that
have previously been shown to be associated with trial quality. For
each quality variable, we created an initial multivariate logistic
regression model and reduced it to a final model. The initial model
contained all the independent variables with p-values,0.2 for the
significance testing results from the univariate analyses (Hosmer
and Lemeshow approach [18]) as well as plausible interaction
terms (US government funding with pharmaceutical funding for
allocation concealment) to address potential effect modification.
We then used backwards stepwise selection with a maximum p-
value set at 0.05 to select the independent variables to include in
each final model while simultaneously avoiding possible colinearity
between variables. As our principal aim was to test the effects of
location on quality parameters, we retained location in the optimal
final model regardless of statistical significance. As our assump-
tions about trial quality are dependent on the overall quality of the
reporting in the articles describing the trials, we included a
variable to indicate whether a flow diagram recommended by
CONSORT was included in the report [19]. This served as a
proxy measure of reporting quality, on the basis of previous
research, [20] and was retained in the final model regardless of
statistical significance. The likelihood ratio and significance values
are presented for each model and the OR, 95% CI and the p-
value are given for each independent variable. To assess the
robustness of our final models, we also performed sensitivity
analyses using different model-building strategies.
Results
Search yield and trial identification
African trials. The search yielded a total of 12,815 records
(7,734 from MEDLINE; 4,594 from EMBASE; 440 from
CENTRAL; and 47 from LILACS). From these, we identified
284 discrete potentially eligible records and after obtaining the full
articles, identified 80 relevant African trials. The reviewers agreed
on 91% of the eligibility of records, indicating very good
agreement. No eligible trials were identified from the LILACS
search.
Trials have been conducted in 18 countries in sub-Saharan Africa
with no trialsconducted inNorth Africa. Table 4 presentsthe country
where each trial took place and whether the study was a single- or
multi-centre trial. Of the ten multicentre, multinational trials which
recruited participants in an African country, three also had sites in
Table 2. Definitions for quality domains.
Domain Sequence of generation
Definition The means by which the sequence of interventions was created
Rating Adequate Inadequate* Unclear*
Computer- or calculator-generated (includes
minimisation and biased urn approaches);
Random number tables; Coin toss; Throwing a
dice; Drawing lots
Days of the week; Medical record
numbers; Alternate days; Birth dates
The process is reported as
‘randomized’ but no details are
provided regarding the method
Domain Allocation concealment
Definition The means by which the intervention assignment is concealed before and including at the point of allocation
Rating Adequate Inadequate* Unclear*
Central randomization with central office retaining
schedule (accept report of centralized process as
‘adequate’); Independent 3
rd party (allocates
intervention and retains schedule; allocator has
no knowledge of patients); Different parties for
randomisation and allocation clearly stated; Secure
computer assisted method e.g. password protected
files; Sequentially numbered, opaque, sealed
envelopes; Serially numbered, identical containers,
allocated sequentially
No separation between person
generating sequence and the allocator
e.g. the person tossing the coin allocates
the participants; Computer programme
with no details provided re protection
and access
Only report ‘sealed envelopes’; The
process is described but it is still not
clear how the process worked; There
is no report of the process.
Domain Masking of assessors
Definition This describes whether the person assessing the primary outcome (e.g. lab analyst, clinician) was blinded to the intervention received by
participants.
Rating Adequate Inadequate* Unclear*
The assessor responsible for the primary outcome
was clearly reported as being unaware of the
treatments received. No assumptions will be made
that this is the case if the trial is reported as
‘double-blind’, or ‘placebo-controlled’
The assessors are clearly reported as
being aware of the treatment received
e.g. the clinician dispensing the
un-blinded intervention was also
responsible for the outcome assessment.
Assessor blinding is not reported
and it is not possible to ascertain
whether the assessors were unaware
of treatment.
*The categories of ‘inadequate’ and ‘unclear’ were collapsed to create a binary variable for each quality domain for use in the logistic regression: ‘adequate (1)’ versus
‘inadequate or unclear (0)’.
doi:10.1371/journal.pone.0003491.t002
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reported simply that they had a ‘North American’ site).
North American trials. The hand-searchers identified 2,456
records as randomized trials and 785 of these were judged eligible
by the first author (Figure 1). We then selected the first 150 of the
randomly sorted 785 records, which yielded 116 discrete North
American trials. Ninety-six trials were based exclusively in the US,
six exclusively in Canada, and 14 were multinational trials
including sites either in Canada or the US, or both. No trials
from Greenland were found. The distribution of key trial
characteristics in the included sample was similar to that in
those records that were excluded from the overall dataset (see
Table 5), indicating a representative sample.
Comparison of African and North American trials
Outliers and missingdata. Of the 80 African and 116 North
American trials, four African and one North American trial were
identified as outliers due to their very large sample sizes. These five
large trials were all community prevention trials with four using
community cluster randomisation and the largest, a vaccine trial,
randomized at an individual level but employing passive outcome
reporting. These trials were sufficiently different from all the other
trialsinsizeforustoexcludethem toavoidpotentiallyobscuringthe
effect of interest in the regression analyses [21].
Information for all variables was complete for the remaining
191 records except for the variable: ‘‘Year of the start of the trial’’.
This was missing for 50 trials in total: 18% (14/76) of the African
trials and 31% (36/115) of the North American trials. This is
potentially an important variable because the time span for our
study covers two decades and it is possible that more recent trials
were more likely to conform to the conduct outlined in reporting
standards such as CONSORT, which were first published in 1996
and revised in 2001 [22]. We found that the year of publication for
the primary report was closely correlated with the year when the
trial commenced for the 141 trials which contained complete
information for both these dates (correlation coefficient=0.89)
and, so, we used the year of publication of the primary report as a
proxy measure for the year in which the trial commenced in the
full dataset of 191 trials. This ranged from 1984 to 2005 but was
skewed by a North American trial (20 participants) published in
1984, five years before the next trial in the sample was published,
in 1989 [23]. We excluded this trial from our detailed analyses,
leaving 190 trials overall (80 African and 114 North American) for
further analysis.
Association between location and reporting of trial
characteristics. Preliminary overview of the trials revealed
that the sources of funding for trials were heterogenous, with many
trials bring funded by multiple agencies. As most North American
(89% (102/114) and African trials (68% (52/76) were funded by
Table 3. Collapse of variable categories into binary format
and numeric codes.
Variable Previous categories Collapsed categories Code
Centre Single centre Single centre 1
Multicentre, single
country
Multicentre 0
Multicentre,
multinational
Multicentre 0
Randomisation
type
Blocked Complex 1
Blocked stratified Complex 1
Simple stratified* Complex 1
Simple Simple 0
Allocation
concealment
Adequate Adequate 1
Inadequate Inadequate or unclear 0
Unclear Inadequate or unclear 0
Random
generation
Adequate Adequate 1
Inadequate Inadequate or unclear 0
Unclear Inadequate or unclear 0
Blinding of
assessors
Yes Yes 1
No No or unclear 0
Unclear No or unclear 0
Local ethics
approval
Reported Reported 1
Not reported Not reported or unclear 0
Unclear Not reported or unclear 0
*the code ‘simple stratified’ refers to randomisation described as ‘stratified’, but
with no report of blocking.
doi:10.1371/journal.pone.0003491.t003
Table 4. African trials by country and single versus multi-
centre status.
Country Number of RCTs
Single centre, single country 46
Botswana 1
Burundi 1
Cameroon 1
Cote d’Ivoire 4
Ethiopia 2
Kenya 7
Malawi 4
Nigeria 1
South Africa 2
Tanzania 4
Uganda 10
Zaire 2
Zambia 4
Zimbabwe 3
Multicentre, single country 24
Cameroon 1
Cote d’Ivoire 2
Kenya 3
Malawi 2
Senegal 1
South Africa 5
Tanzania 2
Uganda 4
Zambia 2
Zimbabwe 2
Multicentre, multinational* 10
*includes Rwanda and Burkina Faso.
doi:10.1371/journal.pone.0003491.t004
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combination of these, we categorised funding to distinguish trials
in two distinct ways: 1) receiving any US government funding
versus not receiving any US government funding and 2) receiving
any pharmaceutical industry funding versus not receiving any
pharmaceutical industry funding.
Table 6 shows the comparison between the trial characteristics
of the two locations for categorical variables. Overall, African trials
were statistically significantly less likely than North American trials
to assess a treatment intervention (OR=0.17; 95%CI: 0.09;0.34;
p,0.01), and statistically significantly more likely to be based in a
single centre (OR=2.40; 95%CI: 1.31;4.31; p,0.01), to report
conducting an a priori power calculation based on a primary
outcome (OR=1.97; 95%CI; 1.09; 3.54), to contain a flow
diagram as recommended by CONSORT (OR=3.93; 95%CI;
1.97; 7.83; p,0.01), and to report adequate generation of the
randomisation sequence (OR=2.75; 95%CI: 1.43; 5.20) and
adequate allocation concealment (OR=3.75; 95%CI: 1.99; 7.05;
p,0.01). North American trials were significantly more likely to
have received funding from the US government (OR=0.35;
95%CI: 0.19; 0.64; p,0.01).
Association between location and trial sample size and
year of publication. Distributions for the number of
participants in both African and North American trials were
positively skewed with many more small trials than large trials.
African trials (median=280; range: 16 to 2,219) were statistically
significantly larger than North American trials (median=101;
range 12 to 2,493; p,0.01).
The year of publication for the primary report for African trials
ranged from 1990 through to 2005, with the most frequent year of
publication being 1999. For North American trials, the year of
publication for the primary report ranged from 1989 through to
2005, with the most frequent publication year being 1998. Overall,
the reports of African trials were published more recently (p,0.01)
with a mean of 1999 for African trials and 1997 for North
American trials.
Comparison between reporting of quality domains in
African and North American trials. Univariate and
multivariate regression analyses were conducted for the quality
domains of allocation concealment, generation of the random
sequence and assessor masking. The information reported on
attrition for the primary outcome was inconsistent across the trial
reports, meaning that the rate of attrition could not be calculated
confidently for many trials and so we did not attempt comparative
analysis for this.
Allocation concealment. Table 7 shows the results of
individual tests of association between reporting of allocation
concealment and each of the variables. It also summarises the final
model; the four variables that jointly showed the strongest
association with reporting of adequate allocation concealment
were: where the trial was conducted, the inclusion or not of a
CONSORT flow diagram, whether the trialists reported
Figure 1. Flow diagram of eligibility selection process for North American trials.
doi:10.1371/journal.pone.0003491.g001
Location Matters
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3491conducting an a priori power calculation based on the primary
outcome, and whether complex randomisation (blocking,
stratification or both) was used. After adjustment, trials
conducted in Africa were independently associated with
reporting of adequate allocation concealment. African trials were
three times more likely to report adequate allocation concealment
than North American trials (OR=3.24; 95%CI: 1.59; 6.60;
p,0.01). Year of publication, on its own, was strongly associated
with allocation concealment, but not after adjusting for the
variables mentioned earlier.
The quality of the journal where the report was published[7], as
measured by whether or not the journal of the primary report was
indexed in the Abridged Index Medicus (AIM) database, did not
affect whether adequate allocation concealment was reported. To
investigate whether reporting the year of the start of the trial was
important, we repeated the analysis for only those trial reports
where we had complete information for the year of the start of the
trial (N=141). The same four variables were jointly selected with
the exception that the inclusion or not of the CONSORT flow
diagram was no longer independently significant.
Random generation. Table 8 shows the results of individual
tests of association between the reporting of generation of the random
sequence and each of the variables. It also summarises the final
model; the three variables that jointly showed the strongest
association with reporting of generation of the random sequence
were: where the trial was conducted, the inclusion or not of a
CONSORT flow diagram and whether the trialists reported
conducting an ap r i o r ipower calculation based on the primary
outcome. After adjustment for other variables, trials conducted in
Africa were significantly more likely to report adequate generation
than North American trials (OR=2.36; 95%CI: 1.20; 4.67;
p=0.01). Trials in which the trialists reported conducting an a
priori power calculation based on the primary outcome were also
significantlymore likelyto reportadequategenerationcomparedwith
trials not reporting this, after adjusting for other variables. Year of
publication was not independently associated with random
generation.
When considering only trials with complete information on the
date of the start of the trial (N=141), we found that the location of
the trial was the only variable significantly associated with
reporting of adequate generation of the random sequence, after
adjusting for other variables. Whether the journal was indexed in
AIM did not affect the results.
Masking of Assessors. Only one independent variable, type
of randomisation, was significantly associated with reporting of
masking of assessors of outcomes in the trials, with (OR=2.33;
95%CI:1.19;4.57) and without (OR=2.22; 95%CI:1.11;4.45)
adjusting for possible confounders. Neither location nor inclusion
of a CONSORT flow diagram were significantly associated with
reporting of masking of assessors of outcomes in the trials, not
individually, nor independently after adjusting for other variables.
Impact of the Principal Investigator. The Principal
Investigator (PI) was clearly reported in very few trials (African:
30% (23/76); North American: 9% (9/114)). As most PIs were first
authors of the primary report, we assumed the first author was the
PI where this was unclear. We had insufficient information to code
PI education or experience, or whether a statistician contributed to
the report, but we explored whether there was a difference
between the quality of those African trials led by a PI resident in
Africa (according to their corresponding address) compared with
African trials led by PIs from outside Africa. Twenty-nine percent
(22/76) of African trials were led by PIs based in Africa, with no
change in this trend over time. Of those African trials which
reported conducting adequate allocation concealment, 31% (12/
39) were led by an African PI. Of the 37 African trials reporting
inadequate or unclear allocation concealment, 27% (10/37) were
led by African PI. This was not a statistically significant difference
(OR=1.20; 95%CI: 0.40; 3.68; p=0.72). Of the trials reporting
adequate generation of the random sequence, 29% (9/31) were led
by an African PI compared to 29% (13/45) of the trials reporting
inadequate or unclear random generation. This was not a
statistically significant difference (OR=1.00; 95%CI: 0.32; 3.07;
p=1.00). We also explored whether North American PIs were
associated with adequate allocation concealment and generation
compared with non-North American PIs in the 76 African trials,
and found no statistically significant differences.
Discussion
To our knowledge, our study represents the first comparative
analysis of the reporting of methodological quality of clinical trials
in resource-rich versus resource-poor parts of the world. It has
uncovered the noteworthy finding that the reports of trials done in
a resource-poor setting show higher methodological reporting
quality than trials done in well-resourced locations.
Strengths and limitations
The strength of our study lies in its comprehensive search for
African and North American trials across multiple databases [24],
rigorous eligibility and data extraction processes conducted by
Table 5. Distribution of key characteristics in the overall North American dataset (785) and the random sample (150) of potentially
eligible North American trials records.
Key characteristics Sampled (N/150)
Not Sampled
(N/634) Sampled (%)
Not Sampled
(%)
Fisher test p-
value
Prevention intervention 15 79 10 12 0.48
HAART as intervention 30 163 20 26 0.17
Behavioural intervention 12 78 8 12 0.16
Definitely in North America 143 596 95 94 0.57
Uncertain that HIV-related trial 10 32 7 5 0.42
Database(s) where record identified 102 429 68 68 0.96*
*Null hypothesis: there was no difference between the number of records identified from each of the seven databases searched for the sampled and not sampled
groups. The p-value is testing that the number of records identified in at least one of the seven different databases did not differ from that of at least one other
database.
doi:10.1371/journal.pone.0003491.t005
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potential confounders and use of strict a priori criteria, based on
previously reported research evidence, to determine the inclusion
of potential confounders in our analyses. All regression analyses
are highly dependent on the choice of variables for inclusion into
the model, and possible residual confounding may be present
especially due to issues of collinearity. We attempted to address
this by consecutively adding or removing variables, and analysing
subsets of individuals (extensive sensitivity analyses). This did not
change the best selection of variables showing the robustness of the
models for allocation concealment and generation of the random
sequence. We did not convert continuous into categorical variables
to avoid the serious biases that this might introduce [26].
However, some detail was inevitably lost when collapsing
categorical into binary variables. For example, Schulz and
colleagues [27,28] pointed out that there may be differences,
particularly in heterogeneity, between trials where allocation
concealment was inadequate compared with trials where alloca-
tion concealment was unclear. However, less than five trials in
both datasets combined were coded as ‘inadequately concealed’,
making lack of retention of these three categories less likely to
result in bias in this study.
As with all observational studies, our findings are limited in that
the associations we found are not necessarily causally related. In
Table 6. Trial characteristics by location of trial (N=190).
Trial characteristic (variable) Africa North America OR* 95% CI* P value
n/N % n/N %
Intervention
Treatment 39/76 51 98/114 86 0.17 0.09; 0.34 ,0.01
Prevention 37/76 49 16/114 14
Centre
Single centre 42/76 55 39/114 34 2.40 1.31; 4.31 ,0.01
Multi-centre, single country & multinational 34/76 44 75/114 66
Type of randomisation
Simple 33/76 43 49/114 43 0.98 0.55; 1.76 0.95
Blocked and/or stratified 43/76 57 65/114 57
Primary outcome clearly defined
Yes, in trial report 61/76 80 77/114 67 1.95 0.98; 3.89 0.06
No, by hierarchy 15/76 20 37/114 33
Power calculation a priori
Yes 42/76 55 44/114 39 1.97 1.09; 3.54 0.03
No/Unclear 34/76 45 70/114 61
CONSORT flow diagram
Reported 31/76 41 17/114 15 3.93 1.97; 7.83 ,0.01
Not reported 45/76 59 97/114 85
Allocation concealment
Adequate 39/76 51 25/114 22 3.75 1.99; 7.05 ,0.01
Inadequate or not reported 37/76 49 89/114 78
Generation of random sequence
Adequate 31/76 41 23/114 20 2.75 1.43; 5.20 ,0.01
Inadequate or not reported 45/76 59 91/114 80
Blinding of assessor
Yes 25/76 33 30/114 26 1.37 0.73; 2.59 0.33
No or unclear 51/76 67 84/114 74
Ethics approval
Local approval obtained 59/76 78 84/114 74 1.24 0.63; 2.45 0.54
No local approval reported 17/76 22 30/114 26
Funder: US Government
Any US government funding 24/76 32 66/114 57 0.35 0.19; 0.64 ,0.01
No US government funding 52/76 68 48/114 43
Funder: Pharmaceutical
Any pharmaceutical funding 42/76 55 71/114 62 0.75 0.41;1.35 0.34
No pharmaceutical funding 34/76 45 43/114 38
*Odds Ratio (OR), 95% Confidence Intervals (95%CI) and p values calculated using univariate logistic regression.
doi:10.1371/journal.pone.0003491.t006
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the quality ofreporting for that trial and may not be a true reflection
of the actual quality of the conduct of that trial. Most journals have
specific limits on the number of words in an article and authors and
editors may choose to reduce the length and detail of the methods
section for a trial in order to leave adequate room for the results,
discussion and conclusions. A consequence of this is that readers
may be forced to regard the trial as being of a lesser methodological
quality and, therefore, they might have less confidence in those
results and conclusions. In order to establish causality, further
research would first be required to compare trial reporting with
actual trial conduct and then to compare these findings across
locations. This would involve appraisal of the trial protocol and its
amendments, observation of the trial conduct and appraisal of the
finaltrialreport.However,giventhatreportsaccessibleinthepublic
domain are the primary source of knowledge about the results of
trials for policy-makers and clinicians, we believe that these are
appropriate for assessing the quality of those trials used to influence
policy and clinical decisions.
Throughout the research process, we based decisions regarding
missing or unclear data on reasonable assumptions, but it is possible
that measurement bias may have been introduced into the analysis,
resulting in over- or under-estimates of the associations we found
depending on the direction of the association in the misclassified
trials [29]. The decision to restrict our searching to bibliographic
databases was primarily pragmatic, leading to all but three of the
included trials being published in journals (three African trials were
unpublished and had been identified from news reports indexed in
MEDLINE).We did not address impact factor directly due to the
conflicting evidence regarding its utility for journal quality
measurement [7,30,31]. Instead, we used a variable coding for
whether a trial report included a CONSORT-recommended flow
diagram as the measure of ‘reporting quality’ and were therefore
able to adjust for this [20]. Furthermore, in the absence of any
accepted, evidence-based classification of journal quality, we also
included whether the journal for each trial’s primary report was in
the Abridged Index Medicus (AIM) in a sensitivity analysis.
Inclusion in the AIM was likely to provide some indication of the
status over time of a journal within the English-speaking world [32].
Possible explanations and implications
The difference in the reporting of methodological quality of
African trials compared with North American trials may not arise
from a single factor, but from a combination of inter-related
Table 7. Univariate & multivariate logistic regression of trial characteristics associated with adequate vs inadequate or unspecified
allocation concealment (N=190).
Variable Univariate analysis
Logistic regression (final model) Likelihood Ratio X
2
(4)=44.55; p,0.01
OR L95%CI U95%CI P value OR L95%CI U95%CI P value
Location
Africa 3.75 2.00 7.06 ,0.01 3.24 1.59 6.59 ,0.01
Intervention
Treatment 0.28 0.15 0.55 ,0.01 . . . .
Centre
Single 0.80 0.43 1.48 0.48 . . . .
Power calculation
Reported 3.95 2.09 7.49 ,0.01 2.32 1.13 4.76 0.02
CONSORT diagram
Reported 4.67 2.33 9.33 ,0.01 2.25 1.02 4.93 0.04
Primary Outcome
Defined 2.32 1.10 4.91 0.03 . . . .
Local ethics
Obtained 3.14 1.37 7.21 0.01 . . . .
Random type*
Complex 3.30 1.70 6.42 ,0.01 2.51 1.17 5.37 0.02
Random generation
Adequate 2.68 1.39 5.14 ,0.01 . . . .
Assessor blinding
Yes 2.29 1.20 4.38 0.01 . . . .
US Government
Any funding 0.68 0.37 1.26 0.22 . . . .
Pharmaceutical
Any funding 1.48 0.79 2.76 0.22 . . . .
Log sample size 4.25 2.25 8.02 ,0.01 . . . .
Year primary report 1.13 1.03 1.23 ,0.01 . . . .
*Random type categorised the random process as 1) simple or 2) complex (included blocking and/or stratification).
doi:10.1371/journal.pone.0003491.t007
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study and what is known from other research, a number of
possible explanations for the observed difference may exist. We
suggest some possible explanations here informed by our findings,
while recognising that further research will be needed to assess
these. Firstly, almost all the African trials were led and funded by
organisations (governmental, non-governmental, and commercial)
which operate in an international domain [15]. The rigorous
process required to procure funding for such trials might make
them more likely to be done by highly-skilled and experienced
investigators. It is possible that locally driven and funded trials
conducted in North America do not have to meet the same
challenges of international peer review and intense competitive
selection. If this is the case, a higher proportion of trials led by
investigators with international reputations may account for the
higher quality present in African trials. As all but two of the
African trials received some funding from international agencies, it
is also possible that those African principal investigators leading
African trials were researchers familiar with the conduct of
international trials and likely to have an international reputation.
Secondly, we showed that the presence of an a priori power
calculation and the use of restricted randomization, were also
significant factors in overall trial quality. These factors may
indicate careful planning and a high level of trial expertise, such
that the investigators leading African trials might be more likely to
have epidemiological or statistical skills than the researchers who
led the trials in North America. However, as noted in our Results
section, we had insufficient information on the qualifications or
experience of the PIs to test this hypothesis.
Thirdly, many African and North American trials involved
more than one agency working collaboratively. A study of 235
gastroenterology trials found that multi-centre trials were of a
higher quality than single-centre trials [2] with the authors
suggesting that more researchers working on a trial ensures strict
and careful planning and conduct of trials. In our study, African
trials were more likely to be based in single centres, but in many of
the African trials collaborating agencies and trial investigators
were from different countries, with European or North American
agencies working in partnership with African researchers [15]. In
contrast, agencies collaborating in the North American trials were
generally all based in the country where the trial was conducted,
either the US or Canada. The challenges associated with working
cross-culturally, especially with reference to African HIV/AIDS
research, have been previously described and include tensions
Table 8. Univariate & multivariate logistic regression of trial characteristics associated with adequate vs inadequate or unspecified
generation of the random sequence (N=190).
Variable Univariate analysis
Logistic regression (final model) Likelihood Ratio X
2
(3)=15.1; p , 0.01
OR L95%CI U95%CI P value OR L95%CI U95%CI P value
Location
Africa 2.73 1.43 5.20 ,0.01 2.36 1.20 4.67 0.01
Intervention
Treatment 0.43 0.22 0.84 0.01 . . . .
Centre
Single 1.37 0.73 2.58 0.33 . . . .
Power calculation
Reported 2.46 1.29 4.70 ,0.01 2.09 1.05 4.17 0.04
CONSORT diagram
Reported 2.00 1.00 4.01 0.05 1.20 0.56 2.59 0.64
Primary Outcome
Defined 1.97 0.90 4.28 0.09 . . . .
Local ethics
Obtained 2.31 1.00 5.34 0.05 . . . .
Random type*
Complex 1.99 1.02 3.88 0.04 . . . .
Allocation concealment
Adequate 2.68 1.39 5.14 ,0.01 . . . .
Assessor blinding
Yes 2.15 1.10 4.19 0.03 . . . .
US Government
Any funding 0.79 0.42 1.49 0.46 . . . .
Pharmaceutical
Any funding 0.72 0.38 1.36 0.31 . . . .
Log sample size 2.53 1.37 4.66 ,0.01 .. . .
Year primary report 1.05 0.96 1.14 0.26 .. . .
*Random type categorised the random process as 1) simple or 2) complex (included blocking and/or stratification).
doi:10.1371/journal.pone.0003491.t008
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different expectations of participation and of transfer of technol-
ogy, of training opportunities and of credit for contributions [33].
We speculate that the cross-cultural collaboration in African trials,
with all the associated competing interests, may create a working
environment compelling investigators to work harder to achieve
their aims, resulting in higher quality trials.
Lastly, a survey in 2000 of The Lancet’s peer referees based in
poor regions, concluded that researchers based in these regions
believe that there is substantial editorial bias against their work
[34]. In a study to evaluate whether publication of studies from
poor countries is dependent on their quality, Yousefi-Nooraie and
colleagues compared the methodological quality and significance
of the results of trials from countries with different development
status [35]. They found that overall, country income had a non-
significant inverse association with the presence of randomization
and a direct significant association with the use of blinding. The
authors suggest that over time, authors from poor countries may
be choosing to selectively report the studies that are larger, have
less serious limitations, and contain positive and significant
findings in international English language journals, because of
the presumption that editors and reviewers will be biased against
their nationality. Should such a bias exist, then it could contribute
to the higher quality of the reporting of African trials since those
African trials that are published will have been well-conducted and
well-reported because these will have been key determinants in
their selection for publication.
Future research
Our findings indicate that location of a trial, or factors inherent
in the location of a trial, may influence the reporting of trial
quality. The findings support the need to plan trials carefully as
evidenced by reporting of methodological quality being associated
with an a priori sample size calculation, valid methods of
randomisation, and clear and complete reporting of the trial as
recommended by CONSORT. Difficulties associated with
identifying trials and missing data will be reduced by prospective
trial registration as advocated by the World Health Organization
[36]. Prospective registration will facilitate further comparative
studies such as this one in the future, as will closer adherence to the
CONSORT standards for reporting trial results. Currently only
one African country has a national prospective trials register and
few African countries have legal imperatives to ensure prospective
registration. Further research is required to delineate whether our
finding is specific to the reporting of HIV/AIDS trials, trials in
Africa compared to North America, or both. Better understanding
of the factors associated with location will allow researchers,
funding agencies, and others to address these factors more
specifically when planning and reporting trials in future.
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